Phase 2/3Recruiting
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC (KANGUROO)
A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)
- Sponsor
- Urovant Sciences GmbH (Industry)
- Enrollment
- 71 planned
- Conditions
- Neurogenic Detrusor Overactivity
- Interventions
- Vibegron
- Ages
- children
- Registry
- NCT05491525
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC
Primary outcomes
- Change from Baseline in maximum cystometric capacity (MCC) based on bladder filling urodynamics
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered